RT Journal Article SR Electronic T1 4th Dose COVID mRNA Vaccines’ Immunogenicity & Efficacy Against Omicron VOC JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.02.15.22270948 DO 10.1101/2022.02.15.22270948 A1 Gili Regev-Yochay A1 Tal Gonen A1 Mayan Gilboa A1 Michal Mandelboim A1 Victoria Indenbaum A1 Sharon Amit A1 Lilac Meltzer A1 Keren Asraf A1 Carmit Cohen A1 Ronen Fluss A1 Asaf Biber A1 Ital Nemet A1 Limor Kliker A1 Gili Joseph A1 Ram Doolman A1 Ella Mendelson A1 Laurence S. Freedman A1 Dror Harats A1 Yitshak Kreiss A1 Yaniv Lustig YR 2022 UL http://medrxiv.org/content/early/2022/02/15/2022.02.15.22270948.abstract AB BACKGROUND Following the emergence of the Omicron variant of concern, we investigated immunogenicity, efficacy and safety of BNT162b2 or mRNA1273 fourth dose in an open-label, clinical intervention trial.METHODS Primary end-points were safety and immunogenicity and secondary end-points were vaccine efficacy in preventing SARS-CoV-2 infections and COVID-19 symptomatic disease. The two intervention arms were compared to a matched control group. Eligible participants were healthcare-workers (HCW) vaccinated with three BNT162b2 doses, and whose IgG antibody levels were ≤700 BAU (40-percentile). IgG and neutralizing titers, direct neutralization of live VOCs, and T-cell activation were assessed. All participants were actively screened for SARS-CoV-2 infections on a weekly basis.RESULTS Of 1050 eligible HCW, 154 and 120 were enrolled to receive BNT162b2 and mRNA1273, respectively, and compared to 426 age-matched controls. Recipients of both vaccine types had a ∼9-10-fold increase in IgG and neutralizing titers within 2 weeks of vaccination and an 8-fold increase in live Omicron VOC neutralization, restoring titers to those measured after the third vaccine dose. Breakthrough infections were common, mostly very mild, yet, with high viral loads. Vaccine efficacy against infection was 30% (95%CI:-9% to 55%) and 11% (95%CI:-43% to +43%) for BNT162b2 and mRNA1273, respectively. Local and systemic adverse reactions were reported in 80% and 40%, respectively.CONCLUSIONS The fourth COVID-19 mRNA dose restores antibody titers to peak post-third dose titers. Low efficacy in preventing mild or asymptomatic Omicron infections and the infectious potential of breakthrough cases raise the urgency of next generation vaccine development.Trial registration number clicaltrials.gov: NCT05231005, NCT05230953Competing Interest StatementGRY recieved an unrelated research grant from Pfizer (on pneumococcal infections), and from Nanosense on volatile organic compoundsClinical Trialclinicaltrial NCT05231005, NCT05230953Funding StatementThis study did not receive any external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Sheba Medical Center IRB gave ethical approval for the work, as well as the national MOH IRB committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study will be available upon reasonable request to the authors